Valneva (NASDAQ:VALN) Stock, Quote.Headers.trade-ideas

VALNEVA SE - ADR

Valneva

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Medical,Development,Laboratory:,Caucasian,Female,Scientist,Looking,Under,Microscope,,Analyzes

Biotech

News

Health Care

Global

General

VALN

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026.

Valneva&#39;s Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

Chikungunya virus

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment.

US Health Agencies Recommend Pausing Valneva&#39;s Chikungunya Vaccine For Older Adults After Adverse Events

Brazil,On,The,World,Globe,-,A,Close,Up,Shot

Movers

Trading Ideas

Valneva&#39;s chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions.

Brazil Approves Valneva&#39;s Mosquito-Borne Chikungunya Vaccine

Valneva SE

Press Releases

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Legal

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Valneva Reports First Quarter 2025 Financial Results and  Provides Corporate Updates

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Valneva to Participate at U.S. and European Investor Conferences in June

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

PARIS:VLA

PARIS:VLAP

Abivax

Altimmune

aTyr Pharma

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Celcuity

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

CytomX Therapeutics

Inventiva S.A. - American Depository Shares

Inventiva

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Myriad Genetics

Oruka Therapeutics

Precigen

Regulus Therapeutics

Regenxbio

Relay Therapeutics

Sana Biotechnology

Tango Therapeutics

Tourmaline Bio

Tyra Biosciences

Verve Therapeutics

Guggenheim

HC Wainwright & Co.

Comments

Valneva

Valneva (NASDAQ:VALN) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell